Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of ethnicity in clinical trials: Delphi survey and consensus statement.

BMJ (Clinical research ed.)·2026
Same author

Harms Reporting Was Frequently Incomplete or Discordant in Biomedical Randomized Trials Published in 2023: A Meta-epidemiological Study.

Journal of clinical epidemiology·2026
Same author

Treating Obesity With Pharmacotherapy: Making Sense of the Evolving Science When Data Are Vast but Direct Comparative Evidence Is Sparse.

Annals of internal medicine·2026
Same author

Influence of Social and Demographic Factors on Retinoblastoma Outcomes in the United States: A Systematic Review.

Cochrane evidence synthesis and methods·2026
Same author

Dynamic lattice disorder overrides energetics for barrierless interfacial charge transfer in 2D hybrid perovskites.

Science advances·2026
Same author

A Systematic Review of Patient-Reported Outcome Instruments Relevant to Glaucoma.

Journal of glaucoma·2026

Related Experiment Video

Updated: Jun 19, 2026

The Measurement and Treatment of Suppression in Amblyopia
08:34

The Measurement and Treatment of Suppression in Amblyopia

Published on: December 14, 2012

Conventional occlusion versus pharmacologic penalization for amblyopia.

Tianjing Li1, Kate Shotton

  • 1Cochrane Eyes and Vision Group US Project, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street. E6006, Baltimore, USA, MD 21205.

The Cochrane Database of Systematic Reviews
|October 13, 2009
PubMed
Summary

Atropine penalization is as effective as conventional occlusion for treating amblyopia (impaired vision). This study found atropine to be a well-tolerated, cost-effective first-line treatment option for amblyopia.

More Related Videos

Stereoacuity Improvement using Random-Dot Video Games
06:25

Stereoacuity Improvement using Random-Dot Video Games

Published on: January 14, 2020

Related Experiment Videos

Last Updated: Jun 19, 2026

The Measurement and Treatment of Suppression in Amblyopia
08:34

The Measurement and Treatment of Suppression in Amblyopia

Published on: December 14, 2012

Stereoacuity Improvement using Random-Dot Video Games
06:25

Stereoacuity Improvement using Random-Dot Video Games

Published on: January 14, 2020

Area of Science:

  • Ophthalmology
  • Clinical Trials
  • Pediatric Medicine

Background:

  • Amblyopia, or 'lazy eye,' is reduced vision in one or both eyes without a clear physical abnormality.
  • It is a common cause of visual impairment in children, necessitating effective treatment.

Purpose of the Study:

  • To compare the efficacy and safety of conventional occlusion therapy versus atropine penalization for amblyopia treatment.
  • To evaluate which treatment offers better visual acuity improvement and tolerability.

Main Methods:

  • Systematic review of randomized and quasi-randomized controlled trials comparing occlusion and atropine penalization for amblyopia.
  • Searched multiple databases including CENTRAL, MEDLINE, EMBASE, and LILACS up to June 2009.
  • Independent data extraction and risk of bias assessment by two authors.

Main Results:

  • Three trials with 525 eyes indicated atropine penalization is comparable in effectiveness to conventional occlusion.
  • While one trial favored atropine, another showed similar visual acuity gains at 6 and 24 months for both treatments.
  • No significant differences were observed in ocular alignment or stereo acuity; atropine showed better compliance and lower cost.

Conclusions:

  • Both occlusion and atropine penalization effectively improve visual acuity in amblyopic eyes.
  • Atropine penalization is a viable and potentially preferable first-line treatment due to its comparable efficacy, better compliance, and lower cost.
  • Further research may be needed to clarify the magnitude of improvement differences across trials.